信達生物(01801.HK)授出49.8萬股受限制股份
格隆匯6月30日丨信達生物(01801.HK)公告,於2025年6月30日,公司根據2024年股份計劃的條款向3名承授人授出35,000份購股權,及向25名承授人授出497,750股受限制股份,購股權的行使價每股股份79.870港元。所有承授人均爲集團非關聯僱員(非高級管理層)。
上述授出購股權及授出受限制股份旨在(a)爲公司提供靈活方式以提供薪酬、激勵、留任、獎勵、補償及╱或提供福利予合資格參與者;(b)通過爲合資格參與者提供可獲得公司持股權益的機會,使該等合資格參與者的利益與公司及股東的利益保持一致;及(c)鼓勵合資格參與者爲公司的長期發展、表現及盈利作出貢獻,爲公司及股東的整體利益提升公司及其股份的價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.